A research team from The Scripps Research Institute (TSRI), Mayo Clinic and other institutions has identified a new class of drugs that in animal models dramatically slows the aging process—alleviating symptoms of frailty, improving cardiac function and extending a healthy lifespan.
The new research was published March 9 online ahead of print by the journal Aging Cell.
The scientists coined the term “senolytics” for the new class of drugs.
“We view this study as a big, first step toward developing treatments that can be given safely to patients to extend healthspan or to treat age-related diseases and disorders,” said TSRI Professor Paul Robbins, PhD, who with Associate Professor Laura Niedernhofer, MD, PhD, led the research efforts for the paper at Scripps Florida. “When senolytic agents, like the combination we identified, are used clinically, the results could be transformative.”
“The prototypes of these senolytic agents have more than proven their ability to alleviate multiple characteristics associated with aging,” said Mayo Clinic Professor James Kirkland, MD, PhD, senior author of the new study. “It may eventually become feasible to delay, prevent, alleviate or even reverse multiple chronic diseases and disabilities as a group, instead of just one at a time.”
Finding the Target
Senescent cells—cells that have stopped dividing—accumulate with age and accelerate the aging process. Since the “healthspan” (time free of disease) in mice is enhanced by killing off these cells, the scientists reasoned that finding treatments that accomplish this in humans could have tremendous potential.
The scientists were faced with the question, though, of how to identify and target senescent cells without damaging other cells.
The team suspected that senescent cells’ resistance to death by stress and damage could provide a clue. Indeed, using transcript analysis, the researchers found that, like cancer cells, senescent cells have increased expression of “pro-survival networks” that help them resist apoptosis or programmed cell death. This finding provided key criteria to search for potential drug candidates.
Using these criteria, the team homed in on two available compounds—the cancer drug dasatinib (sold under the trade name Sprycel®) and quercetin, a natural compound sold as a supplement that acts as an antihistamine and anti-inflammatory.
Further testing in cell culture showed these compounds do indeed selectively induce death of senescent cells. The two compounds had different strong points. Dasatinib eliminated senescent human fat cell progenitors, while quercetin was more effective against senescent human endothelial cells and mouse bone marrow stem cells. A combination of the two was most effective overall.
Next, the team looked at how these drugs affected health and aging in mice.
“In animal models, the compounds improved cardiovascular function and exercise endurance, reduced osteoporosis and frailty, and extended healthspan,” said Niedernhofer, whose animal models of accelerated aging were used extensively in the study. “Remarkably, in some cases, these drugs did so with only a single course of treatment.”
The Latest on: Senolytic agents
via Google News
The Latest on: Senolytic agents
- Senolytic therapies for healthy longevityon May 16, 2019 at 11:41 am
Given that our knowledge of SNCs in vivo is limited, how should researchers identify senolytic drug targets? One strategy is to identify vulnerabilities shared by cancer cells and SNCs and then use ... […]
- Anti-aging effects of compound in some fruits and vegetables verified in novel new researchon October 3, 2018 at 8:08 am
may be an effective anti-aging compound(Credit: Serg64/Depositphotos) New research has revealed that fisetin – a natural flavonoid found in many fruits and vegetables – functions as an effective ... […]
- Senolytic Therapies Seem To Stop Alzheimer's Disease 'In Its Tracks'on September 23, 2018 at 11:23 pm
The scientists at UT Health used senolytic drugs (agents that selectively destroy senescent cells or induce cell death) to clear the senescent cells and tau tangles in Alzheimer's mice. In the end, ... […]
- Senolytic Therapies And The Quest To Cure Agingon September 23, 2018 at 11:23 pm
Though the term “senolytic therapies” may be a bit foreign to the general public, the agents themselves are nothing new to scientists who have been looking to them to find treatments for a host of ... […]
- Insight on Clinical Potential of Senolytic Drugs on Agingon September 5, 2017 at 4:46 pm
The drugs being tested are called senolytic agents, because they target senescent cells. These are cells that have stopped dividing and secrete toxic chemicals that damage adjacent cells. Accumulation ... […]
- New class of drugs targets aging to keep people healthyon September 4, 2017 at 10:38 pm
They can affect other cells in our various organs and tissues. Senolytic drugs are agents capable of killing problem-causing senescent cells in your body without harming your normal, healthy cells. ... […]
- Researchers review the clinical potential of senolytic drugs on agingon September 4, 2017 at 5:11 pm
The drugs being tested are called senolytic agents, because they target senescent cells ... Dr. Kirkland and authors on the review article, “The Clinical Potential of Senolytic Drugs,” acknowledge the ... […]
- Researchers review the clinical potential of senolytic drugs on agingon September 4, 2017 at 5:56 am
Researchers are moving closer to realizing the clinical potential of drugs that have previously been shown to ... The drugs being tested are called senolytic agents, because they target senescent ... […]
- Mayo Clinic researchers review the clinical potential of senolytic drugs on agingon September 4, 2017 at 4:03 am
The drugs being tested are called senolytic agents, because they target senescent cells ... Dr. Kirkland and authors on the review article, "The Clinical Potential of Senolytic Drugs," acknowledge the ... […]
- Researchers review the clinical potential of senolytic drugs on agingon September 3, 2017 at 5:00 pm
The drugs being tested are called senolytic agents, because they target senescent ... (2017, September 4). Researchers review the clinical potential of senolytic drugs on aging. ScienceDaily. ... […]
via Bing News